Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 9/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.31 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5727873 | 1.00 | CAPN1 (0.36) | CAPN1SCN9AS1PR1PSEN1PSEN2 | |
| SCHEMBL7505585 | 0.86 | PSEN1 (0.31) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5728086 | 0.82 | CAPN1 (0.33) | CAPN1CCNE2CCNE1CDK2 | |
| SCHEMBL5725585 | 0.82 | CAPN1 (0.33) | CAPN1CCNE2CCNE1CDK2 | |
| SCHEMBL5725724 | 0.81 | CCNE1 (0.35) | CAPN1S1PR1CCNE2CCNE1CDK2 | |
| SCHEMBL5725975 | 0.70 | CAPN1 (0.33) | CAPN1CCNE2CCNE1CDK2 | |
| SCHEMBL5728145 | 0.70 | CCNE1 (0.32) | CCNE2CCNE1CDK2 | |
| SCHEMBL5727425 | 0.70 | CAPN1 (0.33) | CAPN1CCNE2CCNE1CDK2 | |
| SCHEMBL5726079 | 0.70 | CCNE1 (0.32) | CCNE2CCNE1CDK2 | |
| SCHEMBL5725520 | 0.69 | GSK3B (0.37) | CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1087951-B9 | CARBON SUBSTITUTED AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2006-09-13 | — | — | EP | claimed |
| EP-1087951-B1 | CARBON SUBSTITUTED AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2005-02-09 | — | — | EP | claimed |
| US-20020165259-A1 | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases | RAWLINS DAVID B (US) | 2002-11-07 | — | — | US | claimed |
| US-6407124-B1 | ANTICARCINOGENIC, ANTIPROLIFERATIVE, ANTIINFLAMMATORY, AND ANTIARTHRITIC AGENTS; ALZHEIMER*S DISEASE AND CARDIOVASCULAR DISORDER TREATMENT | BRISTOL-MYERS SQUIBB COMPANY | 2002-06-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165259-A1 | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases | CCNK, CDK2, CCNL2 | CAPN1 1063/4885SCN9A 1437/4885S1PR1 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.